A Study With RO4917523 in Patients With Fragile X Syndrome
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind multiple ascending dose study will evaluate the safety and
tolerability, pharmacokinetics and efficacy of RO4917523 in patients with Fragile X Syndrome.
The patients will be randomized to receive either active drug or placebo. The anticipated
time on study treatment is 6 weeks. The target sample size is <100 patients.